The startup has a broad global development program underway — and the support of more than 20 investment firms — for a treatment that’s approved in many Asian countries but isn’t yet available in the U.S. or Europe.
An article from
Emerging biotech
The startup has a broad global development program underway — and widespread investor support — for a treatment that’s approved in many Asian countries but isn’t yet available in the U.S. or Europe.
Published July 22, 2026
Crystalys Therapeutics is developing a treatment for gout, a form of arthritis that most commonly affects the big toe joint.
Crystalys Therapeutics raises $130M Series B, led by Frazier Life Sciences, to bring gout drug dotinurad to US/EU markets. The…
Crystalys Therapeutics Announces $130 Million Series B Financing to Advance Global Phase 3 Development and Commercialization of…
Cyllene Therapeutics raised €33 million in a Series C and rebranded from EG 427 as it starts a potentially registrational Phase…
Sobi’s plan to introduce a challenger to Amgen’s blockbuster gout drug Krystexxa has been put on hold by the FDA. | Sobi’s plan…
Mineralys Therapeutics first drew attention in 2021 with a bold bet on a new type of hypertension drug. It came with a $1 million…
Claris Bio has appointed veteran CEO Stephen Brady to lead advanced development of what it hopes to be the first drug therapy for…
Crystalys gets $130M to take Sobi-rivaling gout drug to market
Crystalys Therapeutics Announces $130 Million Series B Financing to Advance Global Phase 3 Development and Commercialization of Dotinurad for Gout
TYBR Health Announces $30 Million Series A Financing to Expand Access to the B3 GEL® System
Curis Gains As Blood Cancer Drug Progresses, December Readout in Focus - Curis (NASDAQ:CRIS)
